Questions 488-491: Specify disorder of immune system classification:

Indicate the disorder of the immune system’s disease classification at diagnosis. If the subtype is not listed, report as “other SCID”, “other immunodeficiency” or “other pigmentary dilution disorder” and specify the reported disease in question 489, 490 or 491. If a certain disease becomes a common indication for HCT, the CIBMTR will add the disease as a separate category.

Question 492: Did the recipient have an active or recent infection with a viral pathogen within 60 days of HCT?

Viral infections are caused by exposure to a new virus or reactivation of a dormant virus already present in the body. The most common viral infections are due to HSV (Herpes Simplex Virus), and CMV (Cytomegalovirus). Report “yes” if the recipient had an active or recent infection with a viral pathogen within 60 days of HCT and continue with question 493. If the recipient did not have an active or recent infection with a viral pathogen report “no” and continue to question 494.

Question 493: Specify the viral pathogen (check all that apply):

Specify any viral pathogens causing infection reported in question 492.

Question 494: Has the recipient ever been infected with PCP/PJP:

PCP Pneumocystis is a common fungal infection commonly affecting the lungs. Indicate if the recipient has ever been infected with PCP/PJP.

Question 495: Does the recipient have GVHD due to maternal cell engraftment pre-HCT? (SCID only):

Recipients with SCID often have presence of maternal T lymphocytes (T cells) in the circulation. This is a complication that results from maternal-fetal transfusion and the failure in SCID patients to recognize and to reject foreign cells, allowing maternal T cells to engraft. This is also known as maternal engraftment. This engraftment can induce graft-versus-host disease (GVHD).

Report “yes” if the recipient has a history of or current manifestations of GVHD due to maternal cell engraftment at the last evaluation prior to the preparative regimen and continue to signature line.

If the recipient does not have GVHD due to maternal cell engraftment pre-HCT, report “no” and submit the form.

Section Updates:

Question Number Date of Change Add/Remove/Modify Description Reasoning (If applicable)
. . . . .
Last modified: Dec 22, 2020

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.